What’s new in i.v. immunoglobulin therapy and pemphigus: High-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus
- 1 March 2010
- journal article
- review article
- Published by Wiley in The Journal of Dermatology
- Vol. 37 (3), 239-245
- https://doi.org/10.1111/j.1346-8138.2009.00796.x
Abstract
High-dose i.v. immunoglobulin (HD-IVIG) has several distinguishing therapeutic characteristics including rapid clearance of pathogenic antibody, non-immunosuppressive and less adverse effects. In 2009, the first multicenter, randomized, placebo-controlled, double-blind trial of HD-IVIG for pemphigus was conducted in Japan. This clinical trial has proved that 400 mg/kg per day for 5 days administration of IVIG is effective as an adjuvant therapy with systemic steroid therapy and/or immunosuppressive agents. Among the several mechanisms to explain the mode of action of IVIG, several lines of evidence have suggested that neonatal Fc receptor for immunoglobulin (Ig)G (FcRn) plays an important role for rapid clearance of pathogenic antibody in pemphigus induced by HD-IVIG. Additionally, the long suppression of IgG production induced by HD-IVIG has been observed in some cases. Taking these characteristics into consideration, HD-IVIG, which leads to decreased pathogenic IgG, is recommended to use in combination with oral corticosteroids or other immunosuppressants, which suppress the production of pathogenic IgG. This review summerizes experimental and clinical evidences for major mechanism of action in HD- IVIG and how to use it.Keywords
This publication has 36 references indexed in Scilit:
- High-Dose Intravenous Immunoglobulin (IVIG) Therapy in Autoimmune Skin Blistering DiseasesClinical Reviews in Allergy & Immunology, 2009
- A randomized double-blind trial of intravenous immunoglobulin for pemphigusJournal of the American Academy of Dermatology, 2009
- Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG.European Journal of Dermatology, 2008
- Intravenous Immunoglobulin: Properties, Mode of Action and Practical Use in DermatologyActa Dermato-Venereologica, 2007
- Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune GlobulinThe New England Journal of Medicine, 2006
- The role of IVIg treatment in severe pemphigus vulgarisJournal of the European Academy of Dermatology and Venereology, 2006
- Novel Mechanisms of Target Cell Death and Survival and of Therapeutic Action of IVIg in PemphigusThe American Journal of Pathology, 2005
- IVIg TREATMENT OF PEMPHIGUS: How it Works and How to Use itJournal of Investigative Dermatology, 2005
- Intravenous Immunoglobulin for Treatment of PemphigusClinical Reviews in Allergy & Immunology, 2005
- Corticosteroid-Sparing Effect of Intravenous Immunoglobulin Therapy in Patients With Pemphigus VulgarisArchives of Dermatology, 2002